4Vote!
Business Wire (Free subscription) | 11/16/2009
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that NASDAQ has halted trading of Cerus common stock. The U.S. Food and Drug Administration's (FDA) Blood Products Advisory Committee (BPAC) is meeting today to review and discuss the proposed design for a potential U.S. Phase III clinical trial of platelets treated with the Company’s INTERCEPT...
3Vote!
Medical News Today (Free subscription) | 11/17/2009
Cerus Corporation (NASDAQ:CERS) announced that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.
3Vote!
DeviceSpace (Free subscription) | 11/17/2009
Reuters -- Blood-safety products maker Cerus Corp (CERS.O) said an U.S. advisory committee recommended more stringent safety margins for a late-stage trial of its intercept blood system to treat platelets.
4Vote!
Business Wire (Free subscription) | 11/17/2009
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets. The Committee disagreed with the safety margins for the trial proposed by...
4Vote!
Market Wire (Free subscription) | 11/19/2009
NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of Integrated Device Technology Inc. (NASDAQ: IDTI), Cerus Corporation (NASDAQ: CERS), Synopsys Inc. (NASDAQ:...
3Vote!
Radon Mitigation Pittsburgh (Free subscription) | 11/18/2009
( EMAILWIRE.COM , November 18, 2009 ) Dallas, TX - Cerus Corporation (NASDAQ:CERS) plunged 18.36% to end the day at $2.09 after the company announced that the United States Food And Drug Administration Blood Products Advisory Committee rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential United States Phase III clinical trial of the INTERCEPT...
4Vote!
Stock Market Analysis (Free subscription) | 11/17/2009
... MediaExpress Holdings, Inc. Announces 2009 Third Quarter Financial Results Helicos BioSciences Corporation (HLCS) - Helicos BioSciences Announces the Sale of a Helicos® Genetic Analysis System to the Leiden University Medical Center in the Netherlands NeurogesX, Inc. (NGSX) - NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)...
3Vote!
EmailWire.Com (Free subscription) | 11/15/2009
... () Reports on Stocks to Watch:Green Energy Live Inc. (OTCBB: ), Hong Kong Highpower (AMEX: ), Cerus Corporation(NasdaqGM: ), RINO International Corporation(NasdaqGM: ), Microsemi Corporation(NasdaqGS: ), Cypress Semiconductor Corporati(NasdaqGS: ), Assured Guaranty Ltd. (: ), Goodyear Tire & Rubber Co. (NYSE: )Featured Stock:GREEN ENERGY LIVE, INC.(OTCBB: GELV)For A...
4Vote!
The Earth Times Online Newspaper (Free subscription) | 11/14/2009
... Reports on Stocks to Watch: Green Energy Live Inc. (OTCBB: GELV), Hong Kong Highpower (AMEX: HPJ), Cerus Corporation(NasdaqGM: CERS), RINO International Corporation(NasdaqGM: RINO), Microsemi Corporation(NasdaqGS: MSCC), Cypress Semiconductor Corporati(NasdaqGS: CY), Assured Guaranty Ltd. (NYSE: AGO), Goodyear Tire & Rubber Co. (NYSE: GT) Featured Stock: GREEN ENERGY...
